Cardiología hoy | Blog
IAM sin enfermedad coronaria aterosclerótica obstructiva: ¿cómo debemos actuar?
- Dr. Juan Carlos Rama Merchán
- Cardiología Hoy
Estimulación vagal crónica en la IC con función sistólica deprimida: ensayo NECTAR-HF
- Dr. Alberto Esteban Fernández
- Cardiología Hoy
CoreValve US Pivotal Trial: Resultados a dos años
- Dr. Pablo Avanzas
- Revista Española de Cardiología - Blog
Introduction
The randomized CoreValve trial demonstrated that transcatheter aortic valve replacement (TAVR) resulted in significantly lower mortality compared with surgical AVR at 1 year in patients who were at increased risk for surgery. Longer-term outcomes following TAVR with the self- expanding CoreValve are necessary to further validate this survival advantage.
AATAC-AF: Ablación vs amiodarona para el tratamiento de la fibrilación auricular persistente en pacientes con insuficiencia cardiaca y un dispositivo implantable
- Dr. Pablo Avanzas
- Revista Española de Cardiología - Blog
Introduction
Catheter ablation (CA) represents a valid treatment option in patients with drug-refractory symptomatic atrial fibrillation (AF). The majority of catheter ablation trials have mainly enrolled patients with preserved LVEF and paroxysmal AF. However, a significant number of patients with AF also have heart failure (HF) and rhythm control with antiarrhythmic drugs has not shown satisfactory results in randomized trials both in patients with or without HF. Whether CA is superior to Amiodarone (AMIO) for the treatment of persistent AF in patients with HF is unknown.
PROMISE: Evaluación económica
- Dr. Pablo Avanzas
- Revista Española de Cardiología - Blog
Introduction
The PROMISE trial is an NHLBI-funded randomized comparative effectiveness trial that compared anatomic testing (≥ 64 detector CT angiography) versus functional testing (exercise ECG, stress nuclear, or stress echocardiography) as the initial diagnostic test in patients with new onset symptoms suspicious for coronary artery disease in whom clinicians required diagnostic testing for further evaluation. An economic substudy was conducted to assess economic outcomes and cost effectiveness from a US societal perspective.
ERICCA: Precondicionamiento isquémico y pronóstico en pacientes a los que se les va a realizar cirugía de revascularización coronaria
- Dr. Pablo Avanzas
- Revista Española de Cardiología - Blog
Introduction
There is a need of cardiac protective strategies for high risk patients undergoing cardiac surgery. Remote ischemic conditioning (RIC) supposes a simple non-invasive and low-cost intervention that may improve long-term clinical outcomes in this setting.
DEFLECT III: Evaluación del dispositivo de protección embólica TriGuard en TAVI
- Dr. Pablo Avanzas
- Revista Española de Cardiología - Blog
Introduction
Clinical stroke after TAVR is frequent (4-7% at 30 days in RCTs), generally under-reported (17% after SAVR when evaluated by neurologist), confers 3- to 9-fold increased risk of mortality and 50% occurs peri-procedural. Silent stoke affects 58-100% of patients and are associated with neurocognitive decline, dementia and stroke.
Ubi thrombus, ibi evacua?
- Dr. Agustín Fernández Cisnal
- Cardiología Hoy
El fracaso de la prevención
- Dr. Eduardo Alegría Ezquerra
- Cardiología Hoy
Recientemente se han publicado los resultados de la encuesta EUROASPIRE IV, una iniciativa de la Sociedad Europea de Cardiología que pretende analizar cómo se hace la prevención secundaria de las enfermedades cardiovasculares en Europa. Los resultados arrojados son tan demoledores como los de las tres precedentes.
Experiencia inicial de la reparación valvular mitral transcatéter
- Dr. Pablo Avanzas
- Revista Española de Cardiología - Blog
Introduction
Degenerative MR is common, affecting ~600,000 persons in the U.S. Surgery is the standard of care, and is indicated for patients with symptoms or LV dysfunction. However, there are patients in whom the risk of surgery is prohibitive. The Mitraclip system received commercial approval in October 24, 201, being indicated for symptomatic patients with primary MR ≥3 and prohibitive surgical risk. Our objective was to analyze and report the initial commercial experience with the MitraClip System in the U.S.
Página 206 de 334
Con la colaboración de
Participa
A lo largo de los años, el blog de la SEC se ha revelado como un instrumento ideal para mantenerse al día de las novedades más importantes que se publican en las revistas científicas internacionales y estimular el debate entre los cardiólogos. Por ello, Cardiología hoy es un foro abierto a la participación de todos los profesionales de salud. Si quieres escribir un artículo...